BACKGROUND: Feline oral squamous cell carcinoma (SCC) carries a very poor prognosis with traditional treatments. HYPOTHESIS/ OBJECTIVES: To examine the effectiveness of adding carboplatin to a previously published accelerated radiation protocol in the treatments of oral SCC in cats. ANIMALS: Thirty-one cases of oral SCC in cats. Tumor sites included lingual (n = 9), mandible (n = 10), maxilla (n = 7), tonsil (n = 4), and cheek (n = 1). METHODS: Prospective trial using a planned radiation protocol consisting of 14 fractions of 3.5 Gy given within a 9-day period with the addition of carboplatin given at 90-100 mg/m(2) on day 1 and day 4.5. Treatments were twice daily with a 6-hour delay between treatments. All cats presenting with oral SCC without evidence of distant metastasis were eligible. RESULTS: Median survival for all cats was 163 days (range 53-770 days) with a mean of 319 ± 53 days with significant predictors of survival being site (P = .004) and whether there was a complete response at 30 days (P = .001). Cats with tumors of tonsil origin or cheek responded best to therapy and were long-term survivors with a mean survival of 724 days and the median had not been reached because of continued survival of 4 cats. CONCLUSIONS AND CLINICAL IMPORTANCE: This protocol offers an aggressive yet tolerable treatment of oral SCC in cats that might offer improved survival as compared with previously reported treatments. The long-term survival of cats with tonsillar SCC has not been reported previously.
BACKGROUND: Feline oral squamous cell carcinoma (SCC) carries a very poor prognosis with traditional treatments. HYPOTHESIS/ OBJECTIVES: To examine the effectiveness of adding carboplatin to a previously published accelerated radiation protocol in the treatments of oral SCC in cats. ANIMALS: Thirty-one cases of oral SCC in cats. Tumor sites included lingual (n = 9), mandible (n = 10), maxilla (n = 7), tonsil (n = 4), and cheek (n = 1). METHODS: Prospective trial using a planned radiation protocol consisting of 14 fractions of 3.5 Gy given within a 9-day period with the addition of carboplatin given at 90-100 mg/m(2) on day 1 and day 4.5. Treatments were twice daily with a 6-hour delay between treatments. All cats presenting with oral SCC without evidence of distant metastasis were eligible. RESULTS: Median survival for all cats was 163 days (range 53-770 days) with a mean of 319 ± 53 days with significant predictors of survival being site (P = .004) and whether there was a complete response at 30 days (P = .001). Cats with tumors of tonsil origin or cheek responded best to therapy and were long-term survivors with a mean survival of 724 days and the median had not been reached because of continued survival of 4 cats. CONCLUSIONS AND CLINICAL IMPORTANCE: This protocol offers an aggressive yet tolerable treatment of oral SCC in cats that might offer improved survival as compared with previously reported treatments. The long-term survival of cats with tonsillar SCC has not been reported previously.
Authors: Leah H Ackerman; Carlos H de Mello Souza; Galaxia Cortés-Hinojosa; Marc E Salute; Alexa A Stephen; Elizabeth Anthony; Keijiro Shiomitsu; Rowan J Milner Journal: Can J Vet Res Date: 2022-01 Impact factor: 0.897
Authors: Jacqueline V J Cavalcanti; Kimberly A Selting; Mai T Ngo; Christine K Tran Hoang; David J Schaeffer; Timothy M Fan; Brendan A C Harley; Heidi Phillips Journal: Am J Vet Res Date: 2022-05-14 Impact factor: 1.055
Authors: Megan E Brown; Misty D Bear; Thomas J Rosol; Chris Premanandan; William C Kisseberth; Cheryl A London Journal: BMC Vet Res Date: 2015-08-14 Impact factor: 2.741
Authors: Shirley Chu; Todd N Wylie; Kristine M Wylie; Gayle C Johnson; Zachary L Skidmore; Maren Fleer; Obi L Griffith; Jeffrey N Bryan Journal: Vet Microbiol Date: 2019-11-02 Impact factor: 3.293
Authors: Alycen P Lundberg; Matthew W Boudreau; Kim A Selting; Lindsay E Chatkewitz; Jonathan Samuelson; Joshua M Francis; Elizabeth I Parkinson; Anne M Barger; Paul J Hergenrother; Timothy M Fan Journal: Neoplasia Date: 2021-07-08 Impact factor: 5.715